The Partnership for New York City and the New York City Economic Development (NYCEDC) Corporation announced that the New York City Investment Fund (NYCIF) will provide up to $1.25 million for a BioAccelerate NYC Prize in a competition that will provide funding for biomedical translational research.  The BioAccelerate NYC Prize is a citywide competition targeting […]

If you are a small business and are interested in obtaining early-stage financing to support your cancer research and technology development, you may be in luck. The National Cancer Institute (NCI) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are offering funding opportunities to eligible small businesses and research institutions for […]

In a spate of recent articles, it would seem that the world has come to an end in terms of high-tech IPOs — not to mention venture backing of early-stage start-ups.  Because of the recent market turmoil, the M&A market has has come to a screeching halt and the window of opportunity for IPOs has […]

Yes, the country’s financial system may be in total meltdown right now but your company can still benefit from the Global Cardiovascular Innovation Center (GCIC).  On top of developing and acquiring new technologies, the GCIC also looks to launch new cardio companies and recruit companies with $30 million in investable cash. The GCIC has announced […]

The Ohio Valley Affiliates for Life Sciences Group (OVALS) will host it’s 6th Annual regional conference  “Transformational Research: A Bridge to Building Economies” on April 14-15, 2008, at the Historic Brown Hotel in Louisville, KY.  Topics Include: Future trends in the biotech industry and factors that will shape it A close-up view of NC: key […]

About Biotech talks about Biotech Business Models this week, such as the Platform, Product and Vertical models for early-stage biotech companies. In all cases, patents and IP rights are noted to be at the core of any venture. Noteably is that the Platform business model has persevered, combined with contract research and services for the […]

Peter Zura’s Two-Seventy-One Patent Blog has an interesting note about the valuation (or, overvaluation, as the case may be) of Biotech patents. Zura points to an article from Dominique Patton, questioning whether the current onslaught of high profile patent litigation is causing excessive valuations of the Intellectual Property Rights (IPRs) of technology companies. But, one […]

The biotech industry’s has been putting on pressure to let biotech companies owned by venture capitalists qualify for federal small-business grants. Through the SBIR program, 2.5 percent of the outside research and development budgets of 10 federal agencies is set aside for small businesses, defined by SBA as those with fewer than 500 employees. Specifically, […]